{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,8]],"date-time":"2026-06-08T09:05:12Z","timestamp":1780909512903,"version":"3.54.1"},"reference-count":38,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2026,6,8]],"date-time":"2026-06-08T00:00:00Z","timestamp":1780876800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2026,6,8]],"date-time":"2026-06-08T00:00:00Z","timestamp":1780876800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"funder":[{"DOI":"10.13039\/501100004721","name":"The University of Tokyo","doi-asserted-by":"crossref","id":[{"id":"10.13039\/501100004721","id-type":"DOI","asserted-by":"crossref"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Cancer Chemother Pharmacol"],"DOI":"10.1007\/s00280-026-04912-x","type":"journal-article","created":{"date-parts":[[2026,6,8]],"date-time":"2026-06-08T08:27:43Z","timestamp":1780907263000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Fosnetupitant for long-delayed chemotherapy-induced nausea and vomiting in oxaliplatin-based regimens: a prospective observational study (LODEC-N)"],"prefix":"10.1007","volume":"96","author":[{"given":"Yohei","family":"Iimura","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hirotoshi","family":"Iihara","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Takeshi","family":"Aoyama","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Toshinobu","family":"Hayashi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Masaaki","family":"Ishibashi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chieko","family":"Sasuga","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Naoki","family":"Furukawa","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Eri","family":"Anzai","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yuki","family":"Ijichi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Seiichiro","family":"Kuroda","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,6,8]]},"reference":[{"key":"4912_CR1","doi-asserted-by":"publisher","first-page":"149","DOI":"10.6004\/jnccn.2012.0018","volume":"10","author":"JM Salsman","year":"2012","unstructured":"Salsman JM, Grunberg SM, Beaumont JL, Rogers M, Paul D, Clayman ML, Cella D (2012) Communicating about chemotherapy-induced nausea and vomiting: a comparison of patient and provider perspectives. J Natl Compr Canc Netw 10:149\u2013157. https:\/\/doi.org\/10.6004\/jnccn.2012.0018","journal-title":"J Natl Compr Canc Netw"},{"key":"4912_CR2","doi-asserted-by":"publisher","first-page":"13","DOI":"10.1016\/j.critrevonc.2015.12.001","volume":"99","author":"S Sommariva","year":"2016","unstructured":"Sommariva S, Pongiglione B, Tarricone R (2016) Impact of chemotherapy-induced nausea and vomiting on health-related quality of life and resource utilization: a systematic review. Crit Rev Oncol Hematol 99:13\u201336. https:\/\/doi.org\/10.1016\/j.critrevonc.2015.12.001","journal-title":"Crit Rev Oncol Hematol"},{"key":"4912_CR3","doi-asserted-by":"publisher","first-page":"4472","DOI":"10.1200\/JCO.2006.05.6382","volume":"24","author":"B Bloechl-Daum","year":"2006","unstructured":"Bloechl-Daum B, Deuson RR, Mavros P, Hansen M, Herrstedt J (2006) Delayed nausea and vomiting continue to reduce patients\u2019 quality of life after highly and moderately emetogenic chemotherapy despite antiemetic treatment. J Clin Oncol 24:4472\u20134478. https:\/\/doi.org\/10.1200\/JCO.2006.05.6382","journal-title":"J Clin Oncol"},{"key":"4912_CR4","doi-asserted-by":"publisher","first-page":"1055","DOI":"10.1038\/bjc.1997.507","volume":"76","author":"M de Boer-Dennert","year":"1997","unstructured":"de Boer-Dennert M, de Wit R, Schmitz PI, Djontono J, Stoter G, Verweij J (1997) Patient perceptions of the side-effects of chemotherapy: the influence of 5HT3 antagonists. Br J Cancer 76:1055\u20131061. https:\/\/doi.org\/10.1038\/bjc.1997.507","journal-title":"Br J Cancer"},{"key":"4912_CR5","doi-asserted-by":"publisher","first-page":"100278","DOI":"10.1016\/j.ctarc.2020.100278","volume":"26","author":"K Gupta","year":"2021","unstructured":"Gupta K, Walton R, Kataria SP (2021) Chemotherapy-induced nausea and vomiting: pathogenesis, recommendations, and new trends. Cancer Treat Res Commun 26:100278. https:\/\/doi.org\/10.1016\/j.ctarc.2020.100278","journal-title":"Cancer Treat Res Commun"},{"key":"4912_CR6","doi-asserted-by":"publisher","first-page":"101","DOI":"10.1007\/s10549-013-2727-3","volume":"142","author":"I Kuchuk","year":"2013","unstructured":"Kuchuk I, Bouganim N, Beusterien K, Grinspan J, Vandermeer L, Gertler S, Dent SF, Song X, Segal R, Mazzarello S, Crawley F (2013) Preference weights for chemotherapy side effects from the perspective of women with breast cancer. Breast Cancer Res Treat 142:101\u2013107. https:\/\/doi.org\/10.1007\/s10549-013-2727-3","journal-title":"Breast Cancer Res Treat"},{"key":"4912_CR7","doi-asserted-by":"publisher","first-page":"219","DOI":"10.1007\/s00520-004-0710-6","volume":"13","author":"CC Sun","year":"2005","unstructured":"Sun CC, Bodurka DC, Weaver CB, Rasu R, Wolf JK, Bevers MW, Smith JA, Wharton JT, Rubenstein EB (2005) Rankings and symptom assessments of side effects from chemotherapy: insights from experienced patients with ovarian cancer. Support Care Cancer 13:219\u2013227. https:\/\/doi.org\/10.1007\/s00520-004-0710-6","journal-title":"Support Care Cancer"},{"key":"4912_CR8","doi-asserted-by":"publisher","first-page":"561","DOI":"10.2147\/PPA.S80327","volume":"9","author":"K Kawakami","year":"2015","unstructured":"Kawakami K, Nakamoto E, Yokokawa T, Sugita K, Mae Y, Hagino A, Suenaga M, Mizunuma N, Oniyama S, Machida Y, Yamaguchi T (2015) Patients\u2019 self-reported adherence to capecitabine on XELOX treatment in metastatic colorectal cancer: findings from a retrospective cohort analysis. Patient Prefer Adherence 9:561\u2013567. https:\/\/doi.org\/10.2147\/PPA.S80327","journal-title":"Patient Prefer Adherence"},{"key":"4912_CR9","doi-asserted-by":"publisher","first-page":"1625","DOI":"10.3727\/096504017X15012905098071","volume":"25","author":"K Kawakami","year":"2017","unstructured":"Kawakami K, Yokokawa T, Kobayashi K, Sugisaki T, Suzuki K, Suenaga M, Yamaguchi K, Inoue A, Machida Y, Yamaguchi T, Hama T (2017) Self-reported adherence to capecitabine on XELOX treatment as adjuvant therapy for colorectal cancer. Oncol Res 25:1625\u20131631. https:\/\/doi.org\/10.3727\/096504017X15012905098071","journal-title":"Oncol Res"},{"key":"4912_CR10","doi-asserted-by":"publisher","first-page":"2782","DOI":"10.1200\/JCO.20.01296","volume":"38","author":"PJ Hesketh","year":"2020","unstructured":"Hesketh PJ, Kris MG, Basch E, Bohlke K, Barbour SY, Clark-Snow RA, Danso MA, Dennis K, Dupuis LL, Dusetzina SB, Eng C (2020) Antiemetics: ASCO guideline update. J Clin Oncol 38:2782\u20132797. https:\/\/doi.org\/10.1200\/JCO.20.01296","journal-title":"J Clin Oncol"},{"key":"4912_CR11","doi-asserted-by":"crossref","unstructured":"Herrstedt J, Clark-Snow R, Ruhlmann CH, Molassiotis A, Olver I, Rapoport BL, Aapro M, Dennis K, Hesketh PJ, Navari RM, Schwartzberg L (2004) 2023 MASCC and ESMO guideline update for the prevention of chemotherapy- and radiotherapy-induced nausea and vomiting. ESMO Open 2024 9:102195","DOI":"10.1016\/j.esmoop.2023.102195"},{"key":"4912_CR12","doi-asserted-by":"publisher","first-page":"873","DOI":"10.1007\/s10147-024-02535-x","volume":"29","author":"H Iihara","year":"2024","unstructured":"Iihara H, Abe M, Wada M, Iino K, Akechi T, Imamura CK, Okuyama A, Ozawa K, Kim YI, Sasaki H, Satomi (2024) 2023 Japan Society of clinical oncology clinical practice guidelines update for antiemesis. Int J Clin Oncol 29:873\u2013888","journal-title":"Int J Clin Oncol"},{"key":"4912_CR13","doi-asserted-by":"publisher","first-page":"1274","DOI":"10.1016\/j.ejca.2015.03.024","volume":"51","author":"J Nishimura","year":"2015","unstructured":"Nishimura J, Satoh T, Fukunaga M, Takemoto H, Nakata K, Ide Y, Fukuzaki T, Kudo T, Miyake Y, Yasui M, Morita S (2015) Combination antiemetic therapy with aprepitant\/fosaprepitant in patients with colorectal cancer receiving oxaliplatin-based chemotherapy (SENRI trial): a multicentre, randomised, controlled phase 3 trial. Eur J Cancer 51:1274\u20131282. https:\/\/doi.org\/10.1016\/j.ejca.2015.03.024","journal-title":"Eur J Cancer"},{"key":"4912_CR14","doi-asserted-by":"publisher","first-page":"e215250","DOI":"10.1001\/jamanetworkopen.2021.5250","volume":"4","author":"DS Wang","year":"2021","unstructured":"Wang DS, Hu MT, Wang ZQ, Ren C, Qiu MZ, Luo HY, Jin Y, Fong WP, Wang SB, Peng JW, Zou QF (2021) Effect of aprepitant for the prevention of chemotherapy-induced nausea and vomiting in women: A randomized clinical trial. JAMA Netw Open 4:e215250. https:\/\/doi.org\/10.1001\/jamanetworkopen.2021.5250","journal-title":"JAMA Netw Open"},{"key":"4912_CR15","first-page":"4527","volume":"35","author":"M Maehara","year":"2015","unstructured":"Maehara M, Ueda T, Miyahara D, Takahashi Y, Miyata K, Nam SO, Katsuda T, Kondo H, Miyamoto S (2015) Clinical efficacy of aprepitant in patients with gynecological cancer after chemotherapy using paclitaxel and carboplatin. Anticancer Res 35:4527\u20134534","journal-title":"Anticancer Res"},{"key":"4912_CR16","doi-asserted-by":"publisher","first-page":"1983","DOI":"10.1007\/s00520-010-1042-3","volume":"19","author":"M Majem","year":"2011","unstructured":"Majem M, Moreno ME, Calvo N, Feliu A, P\u00e9rez J, Mangues MA, Barnadas A (2011) Perception of healthcare providers versus patient reported incidence of chemotherapy-induced nausea and vomiting after the addition of NK-1 receptor antagonists. Support Care Cancer 19:1983\u20131990. https:\/\/doi.org\/10.1007\/s00520-010-1042-3","journal-title":"Support Care Cancer"},{"key":"4912_CR17","doi-asserted-by":"publisher","first-page":"139","DOI":"10.1007\/s12032-018-1199-z","volume":"35","author":"M Karayama","year":"2018","unstructured":"Karayama M, Inui N, Tanaka K, Yasui H, Hozumi H, Suzuki Y, Furuhashi K, Fujisawa T, Enomoto N, Nakamura Y, Suda T (2018) Prophylactic aprepitant is better than salvage for carboplatin-based chemotherapy: a propensity score-matched analysis. Med Oncol 35:139. https:\/\/doi.org\/10.1007\/s12032-018-1199-z","journal-title":"Med Oncol"},{"key":"4912_CR18","doi-asserted-by":"publisher","first-page":"410","DOI":"10.1016\/j.lungcan.2015.11.009","volume":"90","author":"H Kusagaya","year":"2015","unstructured":"Kusagaya H, Inui N, Karayama M, Fujisawa T, Enomoto N, Kuroishi S, Nakamura Y, Matsuda H, Yokomura K, Koshimizu N, Toyoshima M (2015) Evaluation of palonosetron and dexamethasone with or without aprepitant to prevent carboplatin-induced nausea and vomiting in patients with advanced non-small-cell lung cancer. Lung Cancer 90:410\u2013416. https:\/\/doi.org\/10.1016\/j.lungcan.2015.11.009","journal-title":"Lung Cancer"},{"key":"4912_CR19","doi-asserted-by":"publisher","first-page":"21","DOI":"10.1186\/s40780-021-00204-z","volume":"7","author":"Y Watanabe","year":"2021","unstructured":"Watanabe Y, Saito Y, Mitamura T, Takekuma Y, Sugawara M (2021) Adding aprepitant to palonosetron does not decrease carboplatin-induced nausea and vomiting in patients with gynecologic cancer. J Pharm Health Care Sci 7:21. https:\/\/doi.org\/10.1186\/s40780-021-00204-z","journal-title":"J Pharm Health Care Sci"},{"key":"4912_CR20","doi-asserted-by":"publisher","first-page":"73","DOI":"10.1007\/s00520-019-04778-1","volume":"28","author":"H Woopen","year":"2020","unstructured":"Woopen H, Richter R, Chekerov R, Inci G, Alavi S, Grabowski JP, Sehouli J (2020) Prognostic role of chemotherapy-induced nausea and vomiting in recurrent ovarian cancer patients: results of an individual participant data meta-analysis in 1213. Support Care Cancer 28:73\u201378. https:\/\/doi.org\/10.1007\/s00520-019-04778-1","journal-title":"Support Care Cancer"},{"key":"4912_CR21","unstructured":"Akynzeo\u00ae (netupitant and palonosetron) prescribing information. Helsinn Therapeutics, Lugano, Switzerland"},{"key":"4912_CR22","doi-asserted-by":"publisher","first-page":"1913","DOI":"10.1007\/s12325-023-02474-5","volume":"40","author":"M Abe","year":"2023","unstructured":"Abe M, Iihara H, Aogi K (2023) Fosnetupitant for the prevention of chemotherapy-induced nausea and vomiting: A short review and clinical perspective. Adv Ther 40:1913\u20131925. https:\/\/doi.org\/10.1007\/s12325-023-02474-5","journal-title":"Adv Ther"},{"key":"4912_CR23","doi-asserted-by":"publisher","first-page":"CD012775","DOI":"10.1002\/14651858.CD012775.pub2","volume":"11","author":"V Piechotta","year":"2021","unstructured":"Piechotta V, Adams A, Haque M, Scheckel B, Kreuzberger N, Monsef I, Jordan K, Kuhr K, Skoetz N (2021) Antiemetics for adults for prevention of nausea and vomiting caused by moderately or highly emetogenic chemotherapy: a network meta-analysis. Cochrane Database Syst Rev 11:CD012775. https:\/\/doi.org\/10.1002\/14651858.CD012775.pub2","journal-title":"Cochrane Database Syst Rev"},{"key":"4912_CR24","doi-asserted-by":"publisher","first-page":"1692","DOI":"10.1002\/cncr.34088","volume":"128","author":"K Matsuura","year":"2022","unstructured":"Matsuura K, Tsurutani J, Inoue K et al (2022) A phase 3 safety study of fosnetupitant as an antiemetic in patients receiving anthracycline and cyclophosphamide: CONSOLE-BC. Cancer 128:1692\u20131698","journal-title":"Cancer"},{"key":"4912_CR25","doi-asserted-by":"publisher","first-page":"1805","DOI":"10.1007\/s00520-011-1278-6","volume":"20","author":"T Hayashi","year":"2012","unstructured":"Hayashi T, Ikesue H, Esaki T, Fukazawa M, Abe M, Ohno S, Tomizawa T, Oishi R (2012) Implementation of institutional antiemetic guidelines for low emetic risk chemotherapy with docetaxel: a clinical and cost evaluation. Support Care Cancer 20:1805\u20131810. https:\/\/doi.org\/10.1007\/s00520-011-1278-6","journal-title":"Support Care Cancer"},{"key":"4912_CR26","doi-asserted-by":"publisher","first-page":"2707","DOI":"10.1007\/s00520-017-3679-7","volume":"25","author":"T Hayashi","year":"2017","unstructured":"Hayashi T, Shimokawa M, Miyoshi T, Toriyama Y, Yokota C, Taniguchi J, Hanada K, Tsumagari K, Okubo N, Koutake Y, Sakata K (2017) A prospective, observational, multicenter study on risk factors and prophylaxis for low emetic risk chemotherapy-induced nausea and vomiting. Support Care Cancer 25:2707\u20132714. https:\/\/doi.org\/10.1007\/s00520-017-3679-7","journal-title":"Support Care Cancer"},{"key":"4912_CR27","doi-asserted-by":"publisher","first-page":"505","DOI":"10.1007\/s00520-023-07978-y","volume":"31","author":"R Chow","year":"2023","unstructured":"Chow R, Yin LB, Baqri W, Huang R, Boldt G, Younus J, Lock M, Prsic E, Zimmermann C, Herrstedt J (2023) Prevalence and predictors of long-delayed (>\u2009120\u00a0h) chemotherapy-induced nausea and vomiting (CINV)-a systematic review and individual patient data meta-analysis. Support Care Cancer 31:505. https:\/\/doi.org\/10.1007\/s00520-023-07978-y","journal-title":"Support Care Cancer"},{"key":"4912_CR28","doi-asserted-by":"publisher","first-page":"1139","DOI":"10.1007\/s00520-018-4403-y","volume":"27","author":"D Tsuji","year":"2019","unstructured":"Tsuji D, Suzuki K, Kawasaki Y, Goto K, Matsui R, Seki N, Hashimoto H, Hama T, Yamanaka T, Yamamoto N, Itoh K (2019) Risk factors associated with chemotherapy-induced nausea and vomiting in the triplet antiemetic regimen including palonosetron or granisetron for cisplatin-based chemotherapy: analysis of a randomized, double-blind controlled trial. Support Care Cancer 27:1139\u20131147. https:\/\/doi.org\/10.1007\/s00520-018-4403-y","journal-title":"Support Care Cancer"},{"key":"4912_CR29","doi-asserted-by":"publisher","first-page":"1171","DOI":"10.1007\/s00520-009-0737-9","volume":"18","author":"PJ Hesketh","year":"2010","unstructured":"Hesketh PJ, Aapro M, Street JC, Carides AD (2010) Evaluation of risk factors predictive of nausea and vomiting with current standard-of-care antiemetic treatment: analysis of two phase III trials of aprepitant in patients receiving cisplatin-based chemotherapy. Support Care Cancer 18:1171\u20131177. https:\/\/doi.org\/10.1007\/s00520-009-0737-9","journal-title":"Support Care Cancer"},{"key":"4912_CR30","doi-asserted-by":"publisher","first-page":"855","DOI":"10.1007\/s10147-015-0786-7","volume":"20","author":"K Tamura","year":"2015","unstructured":"Tamura K, Aiba K, Saeki T, Nakanishi Y, Kamura T, Baba H, Yoshida K, Yamamoto N, Kitagawa Y, Maehara Y, Shimokawa M (2015) Testing the effectiveness of antiemetic guidelines: results of a prospective registry by the CINV Study Group of Japan. Int J Clin Oncol 20:855\u2013865. https:\/\/doi.org\/10.1007\/s10147-015-0786-7","journal-title":"Int J Clin Oncol"},{"key":"4912_CR31","doi-asserted-by":"publisher","first-page":"711","DOI":"10.1111\/cas.12146","volume":"104","author":"I Sekine","year":"2013","unstructured":"Sekine I, Segawa Y, Kubota K, Saeki T (2013) Risk factors of chemotherapy-induced nausea and vomiting: index for personalized antiemetic prophylaxis. Cancer Sci 104:711\u2013717. https:\/\/doi.org\/10.1111\/cas.12146","journal-title":"Cancer Sci"},{"key":"4912_CR32","doi-asserted-by":"publisher","first-page":"116","DOI":"10.1200\/JCO.1997.15.1.116","volume":"15","author":"D Osoba","year":"1997","unstructured":"Osoba D, Zee B, Pater J, Warr D, Latreille J, Kaizer L (1997) Determinants of postchemotherapy nausea and vomiting in patients with cancer. Quality of life and symptom control committees of the National Cancer Institute of Canada Clinical Trials Group. J Clin Oncol 15:116\u2013123. https:\/\/doi.org\/10.1200\/JCO.1997.15.1.116","journal-title":"J Clin Oncol"},{"key":"4912_CR33","doi-asserted-by":"publisher","first-page":"839","DOI":"10.1016\/j.jpainsymman.2013.06.012","volume":"47","author":"A Molassiotis","year":"2014","unstructured":"Molassiotis A, Aapro M, Dicato M, Gascon P, Novoa SA, Isambert N, Burke TA, Gu A, Roila F (2014) Evaluation of risk factors predicting chemotherapy-related nausea and vomiting: results from a European prospective observational study. J Pain Symptom Manage 47:839\u2013848e4. https:\/\/doi.org\/10.1016\/j.jpainsymman.2013.06.012","journal-title":"J Pain Symptom Manage"},{"key":"4912_CR34","doi-asserted-by":"publisher","first-page":"796","DOI":"10.1056\/NEJM198309293091317","volume":"309","author":"JR Sullivan","year":"1983","unstructured":"Sullivan JR, Leyden MJ, Bell R (1983) Decreased cisplatin-induced nausea and vomiting with chronic alcohol ingestion. N Engl J Med 309:796. https:\/\/doi.org\/10.1056\/NEJM198309293091317","journal-title":"N Engl J Med"},{"key":"4912_CR35","doi-asserted-by":"publisher","first-page":"122","DOI":"10.1007\/s12282-019-01001-1","volume":"27","author":"Y Naito","year":"2020","unstructured":"Naito Y, Kai Y, Ishikawa T, Fujita T, Uehara K, Doihara H, Tokunaga S, Shimokawa M, Ito Y, Saeki T (2020) Chemotherapy-induced nausea and vomiting in patients with breast cancer: a prospective cohort study. Breast Cancer 27:122\u2013128. https:\/\/doi.org\/10.1007\/s12282-019-01001-1","journal-title":"Breast Cancer"},{"key":"4912_CR36","doi-asserted-by":"publisher","first-page":"15769","DOI":"10.1002\/cam4.6121","volume":"12","author":"L Zelek","year":"2023","unstructured":"Zelek L, Navari R, Aapro M, Scott\u00e9 F (2023) Single-dose NEPA versus an aprepitant regimen for prevention of chemotherapy-induced nausea and vomiting in patients receiving moderately emetogenic chemotherapy. Cancer Med 12:15769\u201315776. https:\/\/doi.org\/10.1002\/cam4.6121","journal-title":"Cancer Med"},{"key":"4912_CR37","doi-asserted-by":"publisher","first-page":"2780","DOI":"10.1200\/JCO.24.00278","volume":"42","author":"N Inui","year":"2024","unstructured":"Inui N, Suzuki T, Tanaka K, Karayama M, Inoue Y, Mori K, Yasui H, Hozumi H, Suzuki Y, Furuhashi K, Fujisawa T (2024) Olanzapine plus triple antiemetic therapy for the prevention of carboplatin-induced nausea and vomiting: a randomized, double-blind, placebo-controlled phase III trial. J Clin Oncol 42:2780\u20132789. https:\/\/doi.org\/10.1200\/JCO.24.00278","journal-title":"J Clin Oncol"},{"key":"4912_CR38","doi-asserted-by":"publisher","first-page":"e2426076","DOI":"10.1001\/jamanetworkopen.2024.26076","volume":"7","author":"V Ostwal","year":"2024","unstructured":"Ostwal V, Ramaswamy A, Mandavkar S, Bhargava P, Naughane D, Sunn SF, Srinivas S, Kapoor A, Mishra BK, Gupta A, Sansar B (2024) Olanzapine as antiemetic prophylaxis in moderately emetogenic chemotherapy: a phase 3 randomized clinical trial. JAMA Netw Open 7:e2426076. https:\/\/doi.org\/10.1001\/jamanetworkopen.2024.26076","journal-title":"JAMA Netw Open"}],"container-title":["Cancer Chemotherapy and Pharmacology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00280-026-04912-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s00280-026-04912-x","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00280-026-04912-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,6,8]],"date-time":"2026-06-08T08:28:00Z","timestamp":1780907280000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s00280-026-04912-x"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,6,8]]},"references-count":38,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2026,12]]}},"alternative-id":["4912"],"URL":"https:\/\/doi.org\/10.1007\/s00280-026-04912-x","relation":{},"ISSN":["1432-0843"],"issn-type":[{"value":"1432-0843","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,6,8]]},"assertion":[{"value":"17 March 2026","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"27 May 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"8 June 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Hirotoshi Iihara served as a consultant for Astellas Pharma Co., Ltd., Daiichi Sankyo Co., Ltd., Eisai Co., Ltd., and Taiho Pharmaceutical Co., Ltd. Hirotoshi Iihara received lecture fees from Astellas Pharma Co., Ltd.; AstraZeneca plc; Chugai Pharmaceutical Co., Ltd.; Daiichi Sankyo Co., Ltd.; Eli Lilly and Company; Nippon Kayaku Co., Ltd.; Ohara Pharmaceutical Co., Ltd.; Sawai Pharmaceutical Co., Ltd.; Taiho Pharmaceutical Co., Ltd.; and Yakult Honsha Co., Ltd. Yohei Iimura, Takeshi Aoyama, Toshinobu Hayashi, Masaaki Ishibashi, Chieko Sasuga, Naoki Furukawa, Eri Anzai, Yuki Ijichi, and Seiichiro Kuroda have no known competing financial interests or personal relationships that could have appeared to influence the work reported in this paper.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}},{"value":"This study was performed in line with the principles of the Declaration of Helsinki. Approval was granted by the Ethical Review Board of The Institute of Medical Science, the University of Tokyo (approval number: 2023-4-0420). This study was registered in the Japan Registry of Clinical Trials (jRCT) as jRCT1030230130. Written informed consent was obtained from all the patients.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"All patients provided written informed consent.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent to participate"}},{"value":"Not applicable.","order":5,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent to publish"}}],"article-number":"62"}}